Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2022

02-10-2022 | Metastasis | ASO Author Reflections

ASO Author Reflections: Nodal Disease Burden in Patients with Gastrointestinal Stromal Tumor

Authors: Andrew M. Fleming, MD, Zachary E. Stiles, DO, Jeremiah L. Deneve, DO

Published in: Annals of Surgical Oncology | Issue 13/2022

Login to get access

Excerpt

Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms that uncommonly present with lymphatic disease. Certain patient subgroups are known to have a higher risk for nodal metastases, including pediatric patients, those with succinate dehydrogenase (SDH)-deficient GISTs, and KIT/PDGFRA wild-type GISTs.1,2 Currently, no GIST risk stratification nomograms incorporate nodal disease,3 and consensus guidelines only recommend routine lymph node sampling for known SDH-deficient GISTs.4 Predicting nodal metastases and better defining their clinical significance would be valuable in designing higher-fidelity risk stratification tools and directing the operative management of these patients. …
Literature
1.
Boikos SA, Pappo AS, Killian JK, et al. Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: a report from the national institutes of health gastrointestinal stromal tumor clinic. JAMA Oncol. 2016;2(7):922–8.CrossRefPubMedPubMedCentral
2.
Janeway KA, Kim SY, Lodish M, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA. 2011;108(1):314–8.CrossRefPubMed
3.
Gold JS, Gönen M, Gutiérrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009;10(11):1045–52.CrossRefPubMedPubMedCentral
4.
5.
Metadata
Title
ASO Author Reflections: Nodal Disease Burden in Patients with Gastrointestinal Stromal Tumor
Authors
Andrew M. Fleming, MD
Zachary E. Stiles, DO
Jeremiah L. Deneve, DO
Publication date
02-10-2022
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2022
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-12591-0

Other articles of this Issue 13/2022

Annals of Surgical Oncology 13/2022 Go to the issue

Gastrointestinal Oncology

Prognostic Factors and Survival in Gastrointestinal Extrapulmonary Small Cell Carcinoma: A Retrospective Cohort Study

ASO Author Reflections

ASO Author Reflections: Natural Language Processing Aids in the Detection of Incidental Pancreatic Lesions in Cross-Sectional Imaging

Global Health Services Research

Application and Match Rates in the Complex General Surgical Oncology Match

Gastrointestinal Oncology

Impact of Textbook Oncologic Outcome Attainment on Survival After Gastrectomy: A Review of the National Cancer Database

Hepatobiliary Tumors

Hepatectomy is Beneficial in Select Patients with Multiple Hepatocellular Carcinomas

ASO Author Reflections

ASO Author Reflections: The Robotic Versus Laparoscopic Approach to Left and Extended Left Hepatectomy